Towards a novel molecular classification of IBD

Digestive Diseases

Volumn 30, Issue 4, 2012, Pages 425-427

  Vermeire, Severine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Molecular markers; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CROHN DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; ENTERITIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HUMAN; INTESTINE FISTULA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INFLAMMATORY BOWEL DISEASES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84863894144     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000338147     Document Type: Article

References (12)

1. Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
2. Barrett JC, Hansoul S, Nicolae DL, et al: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.
3. Anderson CA, Boucher G, Lees CW, et al: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246-252.
4. Franke A, McGovern DP, Barrett JC, Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010; 42: 1118-1125.
5. Lees CW, Barrett JC, Parkes M, Satsangi J: New IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739-1753.
6. Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, Rutgeerts P, Vermeire S: Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7: 972-980.
7. Cleynen I, Mahachie John JM, Henckaerts L, Van Moerkercke W, Rutgeerts P, Van Steen K, Vermeire S: Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. PLoS One 2010; 5:e12952.
8. Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG: Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121: 4170-4179.
9. Massey DC, Bredin F, Parkes M: Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008; 57: 1294-1296.
10. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group: Sargramostim for active Crohn's disease. N Engl J Med. 2005; 352: 2193-201.
11. Kelan G, Tantisira MD, Lasky-Su J, et al: Genome-wide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011; 365: 1173-1183.
12. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, Ferrante M, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-1619.